2
Announcements
Trials
Browse
Landscape
Status
Completed
1363
Terminated
400
Recruiting
357
Unknown
224
Active not recruiting
187
Withdrawn
101
Not yet recruiting
66
Suspended
14
No longer available
10
Enrolling by invitation
8
Available
7
Approved for marketing
2
Temporarily not available
1
Sponsor Class
INDUSTRY
2
Study Type
Expanded_access
2
Sponsor
Cancer Type
Thoracic
17
Gastrointestinal
13
Other hematologic neoplasm
12
Genitourinary
12
Lymphoid
10
Breast
10
CNS
7
Plasma cell
6
Head & Neck
5
Endocrine
5
Sarcoma
4
Tumor-Agnostic
3
Dermatologic
3
NET
2
Myeloid
2
Gynecologic
2
Other solid neoplasm
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Blast Crisis
1
Interventions
ponatinib
1
nilotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Approved for marketing
×
Myeloid
×
Clear all
NCT01592136
2018-02-06
Expanded Access Program of Ponatinib
Takeda
Approved for marketing
NCT00905593
2012-07-18
ENACT
Novartis
Approved for marketing